2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Natural Language Processing, Biological Processes, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

2089 Transplant reduces treatment burden in high-risk MDS as quantified by time alive and out of hospital (TAOH)

Brian Tshao Do, MD, PhD, Elyse A Olesinski, MD, MPH2, Philip Amrein, MD3, Yi-Bin A Chen, MD4, Jooho Chung, MD, PhD5, Zachariah Defilipp, MD6, Areej R El-Jawahri, MD7, Gabriela Soriano Hobbs, MD8, Hanno Hock, MD, PhD9, Michelle Hyunju Lee, MD10, Steven McAfee, MD11, Kamal Menghrajani, MD12, Rupa Narayan, MD13, Richard Newcomb, MD14, Amir T. Fathi, MD15, Robert P Hasserjian, MD16, Brandon James Aubrey, MBBS PhD FRACP FRCPA17, Andrew M Brunner, MD18
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Massachusetts General Hospital, Boston, Massachusetts, United States
3 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
4 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
5 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
6 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
7 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
8 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
9 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
10 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
11 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
12 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
13 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
14 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
15 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
16 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States
17 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States, Massachusetts General Hospital, Boston, Massachusetts, United States
18 Mass General Brigham Cancer Institute, Boston, Massachusetts, United States

Background: Hematopoietic cell transplantation (HCT) is a potentially curative therapy for myelodysplastic syndrome (MDS), but its application is limited by concerns around clinical burden and reduced quality of life. We hypothesized that time alive and out of hospital (TAOH) may provide an objective measure of a patient’s quality and quantity of life for a given treatment strategy. We retrospectively compared TAOH between patients who underwent chemotherapy followed by HCT versus those treated with chemotherapy alone. We also compared TAOH in TP53-mutated patients, for whom outcomes are typically poor even with HCT.

Methods: 322 patients with MDS were prescribed at least one MDS treatment at Massachusetts General Hospital between June 2015 and December 2025; 146 underwent HCT. We tabulated diagnosis age, sex, IPSS-R score, bone marrow blast percentage, complete blood counts, and the presence of monoallelic or biallelic TP53 mutations. We recorded the date of treatment initiation with hypomethylating agents (HMA) or HCT, progression to AML, last known follow-up, and death. Patients who progressed to AML prior to HMA treatment or HCT were excluded. All inpatient admissions (including ED visits) and outpatient visits (including transfusions or scheduled infusions) up to December 31, 2025 were recorded. All HCT was conducted inpatient. We defined time alive and out of hospital (TAOH) as the total time over a given period (12, 24, or 36 months) during which patients were alive and not in the hospital or at an outpatient visit. TAOH comparisons were adjusted for diagnosis age, sex, IPSS-R score, CBC values, and blast percentage using Poisson regression, accounting for censoring. Hazard ratios for overall survival (OS) were calculated using Cox proportional hazards, adjusted for the confounders above. 

Results: To estimate the additive effect of HCT, we compared patients who received HCT within 12 months of HMA initiation (HMA+HCT; n=73) to HMA without HCT (HMA-only; n=99). Mean 12, 24, and 36-month TAOH starting from the first day of HMA treatment was 7.9, 15.8, and 23.4 months for HMA+HCT patients versus 5.3, 8.2, and 10.2 months for HMA-only patients, corresponding to adjusted rate ratios (RR) of 1.57, 2.03, and 2.44. HMA+HCT patients also had a higher median OS (71.7 vs 10.7 months, HR=0.17, p<0.001). A higher proportion of “alive” days was spent out of the hospital (median 79% vs 56%, p<0.001).

In patients diagnosed with MDS after age 75, HMA+HCT (n=10), compared to HMA-only (n=43), was associated with increased TAOH (8.1/12mo, 15.8/24mo, and 23.2/36mo vs 6.0/12mo, 9.6/24mo, and 11.8/36mo; RR 1.33, 1.71, and 2.04) and longer OS (35.7 vs 14.4 months, HR=0.27, p=0.06). Patients with high-risk MDS (IPSS-R>4.5) treated with HMA+HCT (n=44) versus HMA-only (n=63) also had increased TAOH (7.4/12mo, 14.6/24mo, and 21.4/36mo vs 4.7/12mo, 6.8/24mo, and 7.8/36mo; RR 1.67, 2.27, and 3.00) and OS (68.3 vs 9.5 months, HR=0.16, p<0.001). Across all comparisons, TAOH in the first 12 months of treatment was higher in the HMA+HCT compared to HMA-only cohorts despite the concentrated clinical burden during the first month of transplant.

We explored how HCT impacts TAOH and OS in patients with biallelic p53 inactivation (TP53bi), a group with poor outcomes. Among all HCT recipients, TP53bi patients (n=20) had reduced 12, 24, and 36-month TAOH post-transplant (5.2, 9.5, and 13.4 months vs 8.2, 16.6, and 24.3 months; RR 0.74, 0.67, and 0.59) and median OS (10.7 vs 111.5 months, HR=2.22, p=0.05) compared to TP53wt or TP53mono (n=100). Nevertheless, in TP53bi patients treated with HMA+HCT (n=11) versus HMA-only (n=23), addition of HCT was still associated with increased TAOH (6.8/12mo, 12.7/24mo, and 18.3/36mo vs 4.0/12mo, 4.7/24mo, and 4.7/36mo; RR 1.88, 3.20, and 4.70) and median OS (34.2 vs 5.9 months, HR=0.11, p<0.001). The median percentage of “alive” days out of the hospital also increased (75% vs 45%, p=0.008). 

Conclusion: Despite the clinical burden associated with HCT, treatment with HMA and HCT compared to HMA monotherapy was associated with higher median OS and time alive and out of hospital (TAOH) across MDS patient groups, including those with high-risk IPSS-R scores, advanced age, and biallelic TP53 mutations. Thus, HCT may be associated with not only increased quantity, but also quality, of life in higher-risk patients. TAOH is a promising surrogate metric for treatment burden in future prospective trials evaluating MDS therapies.

Brian Tshao Do, MD, PhD: No relevant conflicts of interest to declare.